LENZ TherapeuticsLENZ -1.03%12 Days Payable is 640.11 as of Mar. 2026, which is 83% below its 10-year median of 3,677.94. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 705 Biotechnology companies, LENZ Therapeutics ranks better than 89.5% on this metric.
The historical rank and industry rank for LENZ Therapeutics's Days Payable or its related term are showing as below:
LENZ'
s Days Payable Range Over the Past 10 Years
Min: 1759.46 Med: 3677.94 Max: 3677.94
Current: 1759.46
During the past 5 years, LENZ Therapeutics's highest Days Payable was 3677.94. The lowest was 1759.46. And the median was 3677.94.
LENZ's Days Payable is ranked better than 89.5% of 705
companies
in the Biotechnology industry
Industry Median: 113.36
vs LENZ: 1759.46
LENZ Therapeutics's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (640.11).
It may suggest that LENZ Therapeuticsdelayed paying its suppliers.
LENZ Therapeutics Days Payable Related Terms
LENZ Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for LENZ Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, LENZ Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LENZ Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where LENZ Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
LENZ Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LENZ Therapeutics (LENZ) has a Days Payable of 640.11 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on LENZ Therapeutics and its competitors. This is 83% below median its historical median of 3,677.94. Over the past decade, LENZ Therapeutics' Days Payable has ranged from 1,759.46 to 3,677.94. According to the industry distribution chart, LENZ Therapeutics ranks #74 out of 705 companies in the Biotechnology industry, placing it in the top 10.5%.
Is LENZ Therapeutics' Days Payable too high?
LENZ Therapeutics' current Days Payable of 640.11 is 83% below median its 10-year median of 3,677.94. Over the past 10 years, this metric has ranged from a low of 1,759.46 to a high of 3,677.94. The Biotechnology industry median Days Payable is 113.36. LENZ Therapeutics' value of 640.11 is 464.7% above this industry median. Based on the distribution chart, LENZ Therapeutics ranks #74 out of 705 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Days Payable compare to KRRO and ANTX?
According to the Biotechnology industry distribution chart, LENZ Therapeutics ranks #74 out of 705 companies for Days Payable. This places LENZ Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.36. LENZ Therapeutics' value of 640.11 is 464.7% above this benchmark. Historically, LENZ Therapeutics' own Days Payable has ranged from 1,759.46 to 3,677.94 over the past decade. While the company's 10-year median is 3,677.94 vs. the industry median of 113.36, LENZ Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LENZ Therapeutics's current Days Payable of 640.11 is 464.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on LENZ Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LENZ Therapeutics's current Days Payable is 640.11, which is 83% below median its own 10-year median of 3,677.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Days Payable of 640.11. The current Days Payable is 640.11, which is 83% below median its 10-year median of 3,677.94 and 464.7% above the Biotechnology industry median of 113.36. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Days Payable is 640.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score
Get the complete analysis for LENZ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LENZ has been successfully added to your 
